Ernexa Therapeutics Inc. (ERNAW) Return on equity 2016–2025
Ernexa Therapeutics Inc. (ERNAW) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-828.0%FY2025 · since FY2016: -76.0% → -828.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -828.0% | +1166.6 pp |
| FY2024 | -1994.6% | -1815.6 pp |
| FY2023 | -179.0% | — |
| FY2021 | -1600.0% | -1525.2 pp |
| FY2020 | -74.8% | -45.2 pp |
| FY2019 | -29.6% | -24.9 pp |
| FY2018 | -4.7% | +21.8 pp |
| FY2017 | -26.5% | +49.5 pp |
| FY2016 | -76.0% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More ERNAW financial trends
ERNAW RevenueERNAW Net incomeERNAW Net marginERNAW Gross profitERNAW Gross marginERNAW Operating incomeERNAW Operating marginERNAW Operating cash flowERNAW Free cash flowERNAW Capital expendituresERNAW Stock buybacksERNAW Dividends paidERNAW Total assetsERNAW Total liabilitiesERNAW Shareholders’ equityERNAW overview →